Human melanoma antigens recognized by T lymphocytes

Keio Journal of Medicine

Volumn 45, Issue 2, 1996, Pages 100-108

  Kawakami, Yutaka ^a   Robbins, Paul F ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

cryptic self determinants; immunotherapy; MHC class I; T cells; tumor antigens

Indexed keywords

CYTOKINE; EPITOPE; INTERLEUKIN 2; MELANOMA ANTIGEN; MUTANT PROTEIN; TUMOR ANTIGEN;

CANCER IMMUNOTHERAPY; CANCER REGRESSION; HUMAN; IMMUNE RESPONSE; MELANOMA; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE;

EID: 0029955865     PISSN: 00229717     EISSN: None     Source Type: Journal    
DOI: 10.2302/kjm.45.100     Document Type: Review

References (78)

1. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP, White DE: Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma Preliminary report. N Engl J Mcd 1988, 319: 1676-1680
2. Rosenberg SA, Yannelli JR, Yang JC, Tpopalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE: Treatment of patients with metastatic melanojma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1995, 86: 1159-1166
3. Rubin JT, Elwood LJ, Rosenberg SA, Lotze MT: Immunohistochemical correlates of response to recombinant interleukin-2 based immunotherapy in humans. Cancer Res 1989, 49: 7086-7092
4. Pockaj BA, Sherry R, Wei J, Yannelli JR, Carter CS, Leitman SF, Carrasquillo JR, White DE, Steinberg S, Rosenberg SA, Yang JD: Localization of Indium-111-labelled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy: augmentation with cyclophosphamide in association with response. Cancer 1994, 73: 1731-1737
5. Kawakami Y, Nishimura I, Restifo NP, Topalian SL, O'Neil BH, Shilyansky J, Yannelli JR, Rosenberg SA: T-cell recognition of human melanoma antigens. J Immunother 1993, 14: 88-93
6. Kawakami Y, Robbins P, Wang RF, Rosenberg SA: Identification of tumor regression antigens in melanoma. Important Adv Oncol 1996: 3-21
7. Anichini A, Maccalli C, Mortarini R, Salvi S, Mazzocchi A, Squarcina P, Herlyn M, Parmiani G: Melanoma cells and normal melanocytcs share antigens recognized by HLA-A2 restricted cytotoxic T cell clones from melanoma patients. J Exp Med 1993, 177: 989-998
8. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA: Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994, 91: 6458-6402
9. Kawakami Y, Eliyahu S, Delgaldo CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor Proc Natl Acad Sci USA 1994, 91: 3515-3519
10. Kawakami Y, Zakut R, Topalian SL, Stotter H, Rosenberg SA: Shared human melanoma antigens. Recognition by tumor infiltrating lymphocytes in HLA-A2.1 transfected melanomas. J Immunol 1992, 148: 639-643
11. O'Neil BH, Kawakami Y, Restifo NP, Bennink JR, Yewdell JW, Rosenberg SA' Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA. J Immunol 1993, 1410: 1418-1993
12. Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB: Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 1983, 9: 689-695
13. Bystryn JC, Rigel D, Friedman RJ, Kopf A: Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol 1987, 123: 1053-1055
14. Richards JM, Mehta N, Ramming K, Skosey P: Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992, 10: 1338-1343
15. Brichard V, Van Pel A, Wolfel T, Wölfel C, De Plaen E, Lethe B, Coulie P, Boon T: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993, 178: 489-495
16. Robbins PF, El-Gamil M, Kawakami Y, Stevens E, Yannelli J, Rosenberg SA: Recognition of tyrosinase by tumor infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res 1994, 54: 3124-3126
17. Bouchard B, Fuller BB, Vijayasaradhi S, Houghton AN: Induction of pigmentation in mouse fibroblasts by expression of human tyrosinase cDNA. J Exp Med 1989, 169: 2029-2042
18. Kang XQ, Kawakami Y, Sakaguchi K, El-Gamil M, Wang RF, Yannclli JR, Appella E, Rosenberg SA, Robbins PF: Identification of a tyrosinace epitope recognized by HLA-A24 restricted tumor-infiltrating lymphocytes. J Immunol 1995, 155: 1343-1348
19. Topalian SL, Rivoltini L, Mancini M, Markus NR, Robbins PF, Kawakami Y, Rosenberg SA: Human CD4+ T cells specifically recognize a shared melanoma - associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 1994, 91: 9461-9465
20. Wolfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Buschenfelde KH, Boon T: Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 1994, 24: 759-764
21. Van Pel A, van der Brugen P, Coulie PG, Brichard VG, Lethe B, van der Eynde B, Uyttenhove C, Renauld JC, Boon B: Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 1995, 145: 229-250
22. Visseren MJ, van Elsas A, van der Voort EIH, Ressing ME, Kast WM, Sehrier PI, Melief CJM: CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J Immunol 1995, 154: 3991-3998
23. Couhe PG, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C, Mattei S, De Plaen ED, Lurquin C, Szikora JP, Reauld JC, Boon T: A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994, 180: 35-42
24. Kawakami Y, Eliyahu S, Sakaguchi K. Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA: Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J Exp Med 1994, 180: 347-352
25. Sensi M, Traversari C, Radrizzani M, Salvi S, Maccalli C, Mortarim R, Rivoltini L, Farma C, Nicolini G, Wolfel T, Brichard V, Boon T, Bordignon C, Aniehini A, Parmiani G: Cytotoxic T lymphocyte clones from different patients display limited T-cell receptors variable gene usage in HLA-A2 restricted recognition of Melan/Mart-1 melanoma antigen. Proc Natl Acad Sci USA 1995, 92: 5674-5678
26. Castelli C, Storkus WJ, Maeurer MJ, Martin DM, Huang EC, Pramanik BN, Nagabhushan TL, Parmiani G, Lotze MT: Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med 1994, 181: 363-368
27. Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins PF, Marincola FM, Salgaller ML, Yannelli JR, Appella E, Rosenberg SA: Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995, 154: 2257-2265
28. Bakker AB, Schreurs MW, De Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ, Figdor CG: Melanocyte lineage-specific antigen gp100 is recognized by melanocyte-derived tumor-infiltrating lymphocytes. J Exp Med 1994, 179: 1005-1009
29. Cox AL, Skipper J, Cehn Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL: Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994, 264: 716-719
30. Adema GJ, de Boer AJ, van't Hullenaar R, Denijn M, Ruiter DJ, Vogel AM, Figdor CG: Melanocyte lineage-specific antigens recognized by monoclonal antibodies NK1-βb, HMB-50, and HMB-45 are encoded by a single cDNA. Am J Pathol 1993, 143: 1579-1585
31. Schaumburg-Lever G, Metzler G, Kaiserling E: Ultrastructural localization of HMB45 binding sites. J Cutan Pathol 1991, 18: 432-435
32. Kobayashi T, Urabe K, Orlow SJ, Higashi K, Imokawa G, Kwon BS, Potterf B, Hearing VJ: The Pme117/Silver locus protein, characterization and investigation of its melanogenic function. J Biol Chem 1994, 269: 29198-29205
33. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang XQ, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA: Recognition of multiple epitopes in the human melanoma antigen gp100 associated with in vivo tumor regression. J Immunol 1995, 154, 3961-3968
34. Salgaller ML, Afshar A, Marincola FM, Rivoltini L, Kawakami Y, Rosenberg SA: Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res 1995, 55: 4972-4979
35. Wang RF, Robbins PF, Kawakami Y, Kang XQ, Rosenberg SA: Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med 1995, 181: 799-804
36. Topalian S, Solomon D, Avis FP, Chang AE, Freeksen DL, Linehan WM, Lotze MT, Robertson CN, Seipp CA, Simon P, Simpson CG, Rosenberg SA: Immunotherapy of patients with advanced cancer using tumor infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol 1988, 6: 839-853
37. Mattes MJ, Thomson TM, Old LJ, Lloyd KO: A pigmentationassociated, differentiation antigen of human melanoma denned by a precipitating antibody in human serum. Int J Cancer 1983, 32: 717-721
38. Hara I, Takechi Y, Houghton AN: Implicating a role for immune recognition of self in tumor rejection: passive immunization against the Brown locus protein. J Exp Med 1995, 182: 1609-1614
39. Jimenez-Cervantes C, Solano F, Kobayashi T, Urabe K, Hearing VJ, Lozano JA, Garcia-Borron JC: A new enzymatic function in the melanogenic pathway. J Biol Chem 1994, 269: 17993-18001
40. Wang R, Parkhurst MR, Kawakami Y, Robbins PF, Rosenberg SA: Utilization of an alternative open reading frame of a normal gene in generating human cancer antigen. J Exp Med 1996, 183: 1131-1140
41. Van Den Eyndc B, Hainaut P, Herin M, Knuth A, Lemoine C, Weynants P, Van der Bruggen P, Fauchet R, Boon T: Presence on a human melanoma of multiple antigens recognized by auto-logous CTL. Int J Cancer 1989, 44: 634-640
42. Van der Bruggen P, Traversari C, Chomez P, Lurquin C, DePlaen E, Van Den Eynde B, Knuth A, Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254: 1643-1647
43. Traversari C, Van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T: A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992, 176: 1453-1457
44. Van der Bruggen P, Szikora JP, Boel P, Wildmann C, Somville M, Sensi M, Boon T: Autologous cytolytic T lymphocytes recognized a MAGE-1 nonapeptide on melanomas expressing Cw1601. Eur J Immunol 1994, 24: 2134-2140
45. Cclis E, Tsai V, Crimi C, DeMars R, Wentworth PA, Chestnut RW, Grey HM, Settc A, Serra HM: Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 1994, 91: 2105-2109
46. Gaugler B, Van Den Eyndc B, Van der Bruggen P, Romcro P, Gaforio JJ, Dc Plaen E, Lethe B, Brasseur F, Boon T: Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994, 179: 921-930
47. Salgaller ML, Weber JS, Koenig S, Yanelli JR, Rosenberg SA: Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide. Cancer Immunol Immunothr 1994, 39: 105-116
48. Van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boel P, de Smet C, Traversari C, Townsend A, Boon T: A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 1994, 24. 3038-3043
49. Boel P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P, Boon T, Van der Bruggen P: BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995, 2: 167-175
50. Van Den Eynde B, Pccters O, De Backer O, Gaugler B, Lucas S, Boon T: A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995, 182: 689-698
51. Coulie PG, Lehmann F, Lethe B, Herman J. Lurquin C, Andrawiss M, Boon T: A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 1995, 92: 7976-7980
52. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, De Plaen E, Hankein T, Meyer zum Buschenfelde KH, Beach D: A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995, 269: 1281-1284
53. Brash DE, Rudolph JA, Lin A, McKenna GJ, Baden HP, Halperin AJ, Ponten J: A role of sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 1991, 88: 10124-10128
54. Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, Appella E, Rosenberg SA: A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996, 183: 1185-1192
55. Kubo RT, Sette A, Grey HM, Appella E, Sakaguchi K, Zhu NZ, Arnott D, Sherman N, Shabanowitz J, Michel H, Bodnar WM, Davis TA, Hunt DF: Definition of specific peptide motifs for four major HLA-A alleles. J Immunol 1994, 152: 3913-3924
56. Kawanishi J, Kato J, Sasaki K, Fujii S, Watanabe M, Niitsu Y: Loss of E-cadherin-dependent cell-cell adhesion due to mutation of the β-catenin gene in a human cancer cell line, HSC-39. Mol Cell Biol 1995, 15: 1175-1181
57. Robbins PF, El-Gamil M, Li YF, Topalian SL, Rivoltini L, Sakaguchi K, Appella E, Kawakami Y, Rosenberg SA: Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24 restricted tumor-infiltrating lymphocytes. J Immunol 1995, 154. 5944-5950
58. Wiedenfeld EA, Fernandez-Vina M, Berzofsky JA, Carbone DP: Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A-0201 peptide consensus motif. Cancer Res 1994, 54: 1175-1177
59. Falk K, Rotzschke O, Stcvanovic S, Jung G, Rammensee HG: Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1993, 351: 290-296
60. Hunt DF, Henderson RA, Shabanowitz J, Sakaguchi K, Michel H, Sevilir N, Cox AL. Appella E, Engelhard VH: Characterization of peptides bound to the Class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992, 255: 1261-1263
61. Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, Kast WM, Mehef CJ, Oseroff C, Yuan L, Ruppert J: The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994, 153: 5586-5592
62. Parker KC, Shields M, DiBrino M, Brooks A, Coligan JE: Peptide binding to MHC class I molecules: implications for antigenic peptide prediction. Immunol Res 1995, 14: 34-57
63. Sercarz EE, Lehmann PV. Ametani A, Benichou G, Miller A, Moudgil K: Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol 1993, 11: 729-766
64. Kawakami Y, Rosenberg SA: Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. Intern Rev Immunol (in press)
65. Kawakami Y, Rosenberg S T-cell recognition of self peptides as tumor rejection antigens. Immunol Res (in press)
66. Moudgil KD, Araetani A, Grewal IS, Kumar V, Sercarz EE: Processing of self-proteins and its impact on shaping the T cell repertoire, autoimmunity and immune regulation. Intern Rev Immunol 1993, 10: 365-377
67. Chan CC, Palestine AG, Nussenblatt RB: Sympathetic ophthalmia and Vogt-Koyanagi-Harada syndrome. In: Tasman W, Jaeger EA, eds, Duane's Clinical Ophthalmology, Philadelphia, J.B. Lippincott Co, 1989
68. Moudgil KD, Sercarz EE: Can antitumor immune responses discriminate between self and nonself? Immunol Today 1994. 15: 353-355
69. Nanda NK, Sercarz EE: Induction of anti-self-immunity to cure cancer. Cell 1995, 82: 13-17
70. Zhai Y, Yang JC, Kawakami Y, SpiessP, Wadsworth SC, Cardoza LM, Coutune LA, Smith AE, Rosenberg SA: Antigen-specific tumor vaccines: development and characterization of recombinant adenoviruses encoding MART-1 or gp100 for cancer therapy. J Immunol 1996, 156: 700-710
71. Irvine K, Rao J, Rosenberg S, Restifo N. Cytokine enhancement of DNA immunization leads to treatment of established pulmonary metastases. J Immunol 1996, 156: 238-245
72. Minev B, McFarland BJ, Spiess PJ, Rosenberg SA, Restifo NP: Insertion signal sequenec fused to minimal peptides elicits specific CD8+ T-cell responses and prolong survival of thymoma-bearing mice. Cancer Res 1994, 54: 4155-4161
73. Suto R, Srivastava PK: A mechanism for the specific immuno-genicity of heat shock protein-chaperoned peptides. Science 1995, 269: 1585-1588
74. Chen W, Khilko S, Fecondo J, Margulies DH, McClusky J: Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class T-peptide affinity and is strongly influenced by nondominant anchor residues. J Exp Med 1994, 180: 1471-1483
75. Parkhurst MR, Salgaller M, Southwood S, Robbins P, Sette A, Rosenberg SA, Kawakami Y: Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A0201 binding residues. J Immunol (in press)
76. Bronte V, Tsung K, Rao JB, Chen PW, Wang M, Rosenberg SA, Restifo NP: IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol 1995, 154: 5282-5292
77. Matzinger P: Tolerance, danger, and the extended family. Annu Rev Immunol 1994, 12: 991-1045
78. Restifo NP, Kawakami Y, Marincola F, Shamamian P, Taggarse A, Esquive IF, Rosenberg SA: Molecular mechanisms used by tumors to escape immune recognition: immunogentherapy and the cell biology of major histocompatibility complex Class I. J lmmunother 1993, 14: 182-190